Silence Therapeutics (SLN)
(Delayed Data from NSDQ)
$5.95 USD
-0.22 (-3.57%)
Updated Aug 4, 2025 04:00 PM ET
After-Market: $5.94 -0.01 (-0.17%) 5:18 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Silence Therapeutics PLC Sponsored ADR's dividend yield currently sits at 0%, which is in-line with the Medical - Drugs industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
SLN 5.95 -0.22(-3.57%)
Will SLN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SLN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SLN
Beat the Market the Zacks Way: Credo, Palantir, Oracle in Focus
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet
SLN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade
Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels
Other News for SLN
Silence Therapeutics Passes Key Resolutions at AGM
SLN: HC Wainwright & Co. Reiterates Buy Rating on Silence Therapeutics | SLN Stock News
SLN: Chardan Capital Maintains Buy Rating and $35 Price Target for Silence Therapeutics | SLN ...
Buy Rating on Silence Therapeutics: Promising Developments in Divesiran and Zerlasiran Programs
Promising Phase 1 Data and Strong Mechanistic Rationale Justify Buy Rating for Silence Therapeutics’ Divesiran in Polycythemia Vera